From major study publications and FDA decisions in 2022 to conference sessions and expert interviews, NeurologyLive® reported on the latest developments in movement disorders, a field that experienced a turbulent twelve months in the drug development pipeline amid progress in other areas. Click here to take a look at the most-read news in movement disorders in 2022.

Dedicated to the vision of becoming the last generation with Huntington's disease

HDSA’s National Youth Alliance (NYA) motivates youth, who are impacted by Huntington’s disease, to get involved in their local HDSA Chapters, Affiliates and Support Groups through education, fundraising and advocacy efforts.

Since 2004, NYA has grown from a small group to over 500 members. It is their mission to support young people within the HD community, as well as inspire the youth of HDSA to get involved in the battle against HD and be proactive in this fight. They are dedicated to making theirs the last generation with Huntington’s disease.

The NYA provides a wide variety of ways for the youth of HDSA to become motivated. Click here to learn more.

Statistical models used to predict Friedreich’s ataxia progression

Researchers have developed statistical models to help predict the progression of Friedreich’s ataxia using data such as age at disease onset and genetic information.

Although the models are not yet accurate enough to be employed in clinical use, the researchers said this is a first step toward individualized medicine for the disease. Click here to learn more.

Insightec receives FDA approval to treat essential tremor patients’ second side

Insightec recently announced it has received additional US Food and Drug Administration (FDA) approval for treatment of essential tremor using its Exablate Neuro platform.

Essential tremor commonly affects both sides of the body, and this new FDA approval will allow patients to have their second side treated at least nine months after treatment of the first side. Click here to read more.

Duopa found to quickly ease motor fluctuations in Phase 3 trial

One year of treatment with Duopa, a levodopa/carbidopa intestinal gel, led to fast and sustained reductions in motor fluctuations and improved symptom control throughout the day among people with advanced Parkinson’s disease. 

The new findings have “important implications for improving patients’ [quality of life] and ability to perform [activities of daily living],” researchers wrote. Click below to read more. Click here to learn more.